Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab


  • Gary H. Lyman
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_4052-2



Neutropenia is an inherited or acquired condition manifested by low numbers of circulating white blood cells known as neutrophils. The absolute neutrophil count (ANC) may be estimated directly or as the product of the total white blood cell count and the fraction of polymorphonuclear cells and band forms in the blood count differential and is generally expressed as the number of cells per mm3. The common toxicity criteria established by the US National Cancer Institute grade neutropenia as grade 0 for ≥2,000/mm3; grade 1 for ≥1,500–<2,000/mm3; grade 2 for ≥1,000–<1,500/mm3; grade 3 for ≥500–<1,000/mm3; and grade 4 for <500/mm3. However, the term neutropenia clinically is generally reserved for ANC <1,500/mm3 (grades 2 or greater).



Normal hematopoiesis is characterized by the controlled proliferation and maturation of multiple cell lines critical to the development of the healthy individual....


Febrile Neutropenia Aplastic Anemia Total White Blood Cell Count Myeloid Cell Line Mature Neutrophil 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Balducci L, Hardy CL, Lyman GH (2005) Hemopoiesis and aging. Cancer Treat Res 124:109–134CrossRefPubMedGoogle Scholar
  2. Bodey GP, Buckley M, Sathe YS et al (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340CrossRefPubMedGoogle Scholar
  3. Infectious Diseases Society of America (2002) Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751CrossRefGoogle Scholar
  4. Kuderer NM, Dale D, Crawford J et al (2006) The morbidity, mortality and cost of febrile neutropenia in cancer patients. Cancer 106:2258–2266CrossRefPubMedGoogle Scholar
  5. Lyman GH, Kuderer NM, Djulbegovic B (2002) Prophylactic granulocyte colony-stimulating factor in patients receiving dose intensive cancer chemotherapy: a meta-analysis. Am J Med 112:406–411CrossRefPubMedGoogle Scholar
  6. Smith TJ, Khatcheressian J, Lyman GH et al (2006) Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Public Health Sciences and Clinical Research Divisions, Hutchinson Institute for Cancer Outcomes ResearchFred Hutchinson Cancer Research CenterSeattleUSA